The Effect of Sihogayonggolmoryeo-tang on the Anxiety of Hwa-byung

NCT ID: NCT01362114

Last Updated: 2012-04-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

160 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-07-31

Study Completion Date

2012-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In this randomized, double blinded, Placebo-control Trial, the investigators planned to give Sihogayonggolmoryeo-tang extract or controlled medication on the Anxiety of Hwa-byung.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hwa-byung

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Sihogayonggolmoryeo-tang extract

* name of product: 'SIHOGAYONGGOLMORYU TANG EXTRACT GRAN'
* standard code for item: 200005676
* shape, type: extract(brown)
* usage, content: adults;three times a day, each taken before or between meals
* dose, standard: 2.5g for each sack, capsulated
* storage : airtight container, stored in room temperature
* expiration date : 36months after manufacture
* macufacturing company: KyungBangnShinYak inc.

Group Type EXPERIMENTAL

SIHOGAYONGGOLMORYU TANG EXTRACT GRAN

Intervention Type DRUG

three times a day, AC 30 min., 4 capsules taken each time (4capsules=2.5g), 8 weeks

Placebo; corn flour,

* raw material: total contents(500㎎); cornstarch 50.0%(250.0㎎), 당수화물 49.45%(247.25㎎), caramel pigment 0.5%(2.5㎎), SsangHwa fragrance 0.05%(0.25㎎)
* shape, type: extract(brown)
* usage, dose: adults: three times a day, 1 sack before or between meals
* dose, standard: 2.5g for each sack, capsulated
* storage : airtight container, stored in room temperature
* expiration date : 36 months after manufacture
* manufacturing company: KyungBangnShinYak inc.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type OTHER

three times a day, AC 30 min., 4 capsules taken each time (4capsules=2.5g), 8 weeks.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

SIHOGAYONGGOLMORYU TANG EXTRACT GRAN

three times a day, AC 30 min., 4 capsules taken each time (4capsules=2.5g), 8 weeks

Intervention Type DRUG

Placebo

three times a day, AC 30 min., 4 capsules taken each time (4capsules=2.5g), 8 weeks.

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

standard code for item: 200005676

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* male or female aged 20-65
* subjects who meet structured interview criteria for Hwa-Byung Diagnosis
* subjects who have axiety (more than 17 score in HAMA)

Exclusion Criteria

* duration of illness less than 6 months
* current or past history of delusions, hallucination
* past history of at least one manic episode, hypomanic episode, or mixed episode
* current or past history of alcohol abuse or alcohol dependence history
* taking substances(e.g. steroids) which might affect symptoms
* medical conditions(e.g. hyperthyroidism, hypothyroidism, heart disease) that might affect symptoms
* current with hepatoma, hepatic cirrhosis, chronic renal failure, congestive heart failure
* pregnancy, lactation, women not using medically accepted means of birth control
* considered not apt to carry out clinical trial
Minimum Eligible Age

20 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Korea Health Industry Development Institute

OTHER_GOV

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

In-Chul Jung

Professor of Oriental Hospital of Daejon University

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

In-Chul Jung, Ph.D

Role: PRINCIPAL_INVESTIGATOR

Oriental Hospital of Daejon University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Oriental Hospital of Daejon University

Daejeon, Choong-Chung-Do, South Korea

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

South Korea

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

BOK NAM SEO

Role: CONTACT

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Dae-Myung Park

Role: primary

82-42-470-9562

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

B080009

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.